Cystic fibrosis (CF) is an autosomal recessive disease that affects multiple organ systems, including the lungs, due to the development of thick, viscous secretions. 1 Airway secretions allow persistent bacterial infections to develop and lead to progressive decline in lung function punctuated by exacerbations that may require hospitalization for IV antibiotic therapy. Acute pulmonary exacerbations (APEs) are a leading cause of morbidity and mortality in patients with CF. [1] [2] [3] [4] The most common organisms found during an APE are Staphylococcus aureus and Pseudomonas aeruginosa. S aureus is more common among children, whereas P aeruginosa becomes more predominant in adults. 5 Chronic bacterial infections and the multiple courses of antibiotics taken by patients with CF increase the risk for development of multidrug-resistant pathogens. 6 In adult patients with CF, current recommendations are to combine an antipseudomonal beta-lactam (BL) and an aminoglycoside (AMG) for the treatment of an APE to target P aeruginosa.
1,2,6
Compared with patients without CF, those with CF have differences in pharmacokinetic variables, including a greater volume of distribution and increased total body clearance for most antibiotics, leading to a shorter elimination half-life and higher dose requirements. [7] [8] [9] Enhanced clearance rates are seen with both BLs and AMG antibiotics, [10] [11] [12] [13] but BLs exhibit time-dependent properties with bactericidal activity that increases with time above the minimum inhibitory concentration (T > MIC). 14 Therefore, administration of BL antibiotics via continuous infusion maximizes the T > MIC and optimizes bactericidal activity. 15 Current guidelines do not recommend continuous infusion BLs 2 ; however, continuous infusion BLs have shown efficacy in small reported series of patients with CF. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Nevertheless, the majority of reports describe few patients with CF and single determinations of clearance.
The present study examined the clearance rates of continuous infusion BL and AMG antibiotics during the 10-to 14-day treatment of an APE in adult patients with CF. We investigated changes in clearance with continued exposure to antibiotics and explored potential associations between serum creatinine (SCr) and creatinine clearance (CrCl) measurements with clearance rates of AMG and continuous infusion antipseudomonal BLs. We hypothesized an inverse relationship between changes in continuous infusion BL and AMG clearance rates as well as a correlation between changes in antibiotic clearance and renal function.
Patients and Methods

Study Setting and Population
The study included patients at least 18 years of age with CF admitted to the University of Utah Hospital for an APE between January 1, 2008, and May 15, 2014, who were treated with an IV AMG in addition to a continuous infusion antipseudomonal BL. The BLs included aztreonam, ceftazidime, meropenem, piperacillin/tazobactam, and ticarcillin/clavulanate. These patients were included if they had both AMG and BL serum levels drawn on day 2 and day 7 of antibiotic therapy. Repeat antibiotic levels are a consistent practice at our institution, with AMG levels specifically timed at 3 and 10 h postdose. For patients with multiple admissions during the study period, data from the most recent admission were used. Pregnant patients and recipients of dual BL therapy or concurrent vancomycin were excluded. The University of Utah Institutional Review Board approved this study (University of Utah Institutional Review Board 0007667) and deemed it exempt from informed consenting procedures.
Data Sources
We 
Outcomes
The primary outcome was change in clearance rates of the continuous infusion BL from day 2 to day 7 of APE treatment. Secondary outcomes included change in tobramycin clearance rates within the same time period and change in percent predicted FEV 1 (FEV 1 %) between admission and discharge. Equations from the Third 
National Health and Nutrition Examination Survey were used to normalize FEV 1 to FEV 1 % because these were the values used to make clinical decisions throughout the study period. 34 
Statistical Analysis
A paired samples t test was used to compare day 2 and day 7 BL and tobramycin clearance rates as well as admission and discharge FEV 1 %. A one-way analysis of variance was conducted to compare the change in clearance rates for all BLs. Given the inclusion of any AMG dosing strategy, a sensitivity analysis was performed in which those who received multiple daily doses of an AMG antibiotic were excluded. Pearson correlation coefficient was used to evaluate associations between change in SCr or CrCL and change in antibiotic clearance rates from day 2 to day 7.
Multivariable linear regression of the change in BL clearance was performed as a function of change in tobramycin clearance rates and CrCL adjusting for age, sex, weight, CF genotype (categorized into mutually exclusive genotype groups), and admission number (number of distinct hospitalizations for each patient during the study period). Adjustments were also made for concurrent nephrotoxic agents, including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, diuretics, nonsteroidal antiinflammatory drugs, sulfamethoxazole/trimethoprim, rifampin, and contrast media. All model covariates were chosen a priori based on potential confounding factors. There was no evidence of heteroscedasticity, multicollinearity, or other deviations from linear regression assumptions.
Results
All eligible patients were included in the study (N ¼ 162) ( Table 2) . Table 3 summarizes the antibiotics used along with average initial total daily doses for the selected APE per patient during the study period. Of the BLs, meropenem was used most often (45.7%), followed by piperacillin/tazobactam (19.8%), ticarcillin/ clavulanate (19.1%), ceftazidime (11.1%), and, finally, aztreonam (4.3%).
Measured serum BL concentrations indicated that the intended target serum level was attained about 65% of the time (e -Fig 1) . The mean clearance rate for continuous infusion BLs increased 20.7% from day 2 to day 7 (95% CI, 11.42 to 32.49; P < .001) (Fig 1) . There was no difference in the change in clearance rates across BL antibiotics (P ¼ .499) ( Table 4 Fig 2) . More patients who received piperacillin/tazobactam had a dose increase (84.38%) compared with those who received other BLs. Unlike other BL groups, these dose increases led to an increase in serum levels above goal, rather than within goal.
Tobramycin clearance rates decreased 6.3% from day 2 to day 7 (95% CI, -12.49 to -4.45; P < .001 (Fig 1) . The mean decrease in tobramycin clearance of -7.97 AE 25.28 mL/min lead to a mean dose reduction of 5.36%. Tobramycin dosing was decreased in 83 patients (51.2%), maintained in 37 patients (22.8%), and increased in 42 patients (25.9%). Nineteen patients (11.9%) admitted prior to 2010 received tobramycin dosed every 8 to 12 h. A sensitivity analysis excluding patients dosed more than once daily found a mean change in tobramycin clearance of -6.22 mL/min (P ¼ .004), which was similar in magnitude and statistical significance compared with the original result. Three patients (1.9%) received amikacin rather than tobramycin and had a median reduction in amikacin clearance of 23.8 mL/min (25% decrease) leading to a median dose reduction of 12.1%. Serum AMG levels and Genotypes not including dF508 or G551D. Although the remainder of patients did not meet their FEV 1 % goal, only 10 (6.2%) had a decrease in FEV 1 % between admission and discharge. Of note, six of these patients did not achieve target antibiotic levels.
The change in BL clearance between day 2 and day 7 was evaluated, controlling for several variables identified as possible confounders (Fig 2) . Thirtyseven patients (22.8%) received concurrent nephrotoxic agents (sulfamethoxazole/trimethoprim or rifampin) during the treatment period, which seemed to have no significant impact on the change in BL clearance (P ¼ .398 and P ¼ .096, respectively). The regression model results revealed a significant impact of "other" genotype (Q493X/1154insT, 1717-1G/A/ 3659delC, E60X/R1158X, R553X/P574H, Q493X/ 3849þ10kbC/T, N1303K/M470V, and S492F/ M470V) on the change in BL clearance (P ¼ .043). This finding indicates that mean changes in BL clearance rates are 53.61 mL/min less for those with "other" genotypes compared with patients with homozygous dF508 genotype.
As shown in e- Figure 4 , no statistically significant correlation was identified between the change in SCr and the change in antibiotic clearance rates for BL (r ¼ 0. Figure 1 -Changes in antibiotic clearance rates (mean AE SD) between day 2 and day 7 or therapy. A statistically significant increase in BL clearance rates occurred (P < .001) while AMG clearance rates decreased (P < .001) despite an increase in mean SCr and a decrease in mean CrCl. AMG ¼ aminoglycoside; BL ¼ beta-lactam; CrCl ¼ creatinine clearance; SCr ¼ serum creatinine. Data are presented as mean AE SD. See Table 1 for expansion of other abbreviation.
chestjournal.org
CrCL and the change in antibiotic clearance rates (r ¼ 0.12, P ¼ .122 for BL and r ¼ -0.09, P ¼ .240 for AMG).
Discussion
These study data showed that BL clearance rates changed during the period of treatment for a CF APE. Mean BL clearance rates increased > 20% within the first week of treatment, which led to a dose adjustment in about 50% of patients and a mean increase in BL dose by nearly 20%. The dose adjustments made to piperacillin/tazobactam led to more supratherapeutic serum levels and fewer levels achieving goal, which suggests room for improvement in the identification of an optimal dose of this antibiotic. Simultaneously, AMG clearance rates also changed. However, contrary to mean BL clearance rates, mean AMG clearance rates decreased by about 6% during the same time frame and led to a 5% decrease in AMG dose. Monitoring of BL and AMG serum levels and calculation of their corresponding clearance rates are needed to optimize antibiotic dosing.
According to our results, changes in antibiotic clearance rates are unrelated to changes in SCr and CrCL levels. Between day 2 and day 7, mean SCr values increased 0.04 mg/dL, leading to a calculated decrease in mean CrCL level of 4.94 mL/min. AMGs are almost entirely eliminated via glomerular filtration, 35 which may explain the small decrease in mean AMG clearance rates. However, BL antibiotics undergo glomerular filtration as well as tubular secretion. 36 We hypothesized that this additional mechanism of drug excretion may contribute to the change in BL clearance rates.
The mean increase of 12.2% predicted in FEV 1 is both statistically and clinically significant and compares favorably with other reports. 37, 38 Finding this improvement in FEV 1 % is a promising piece of evidence supporting the use of continuous infusion BL antibiotics during APE treatment. However, we cannot directly compare these results with results from the use of conventionally dosed BLs. Confirmation in a randomized clinical trial is warranted.
The finding for "other" genotypes implies a lower change in BL clearance compared with patients with homozygous dF508 genotype. However, this result must be interpreted with caution given the small sample size. The reason for this finding is unclear as it is the combined effect of individual genotypes in the group, none of which was frequent enough to allow for more detailed analyses. To our knowledge, no literature exists regarding change in continuous infusion BL clearance rates in relation to specific genetic mutations.
Our study has several strengths. First, we used a wellannotated dataset, including patient genotypes. All patients admitted for the treatment of an APE without contraindications to BL and AMG therapy had the requisite BL and AMG levels because obtaining antibiotic levels on day 2 and day 7 of APE treatment is the standard of practice at our institution. Calculation of antibiotic clearance rates was also standardized with the creation of calculators, along with training for any pharmacist taking care of these study patients with CF on how to use these calculators and adjust antibiotic dosing based on drug levels. In terms of data collection, templates for progress notes on patients with CF allowed for consistent documentation of pharmacokinetic information and efficient data collection.
A limitation to the present study is that we could not include all antipseudomonal BLs because some (eg, imipenem, cefepime) are not routinely used at our institution. Ticarcillin/clavulanate was used in some of the study patients, but it is no longer available. 39 Prior to 2010, tobramycin was dosed in every 8-to 12-h intervals; however, sensitivity analyses excluding these patients did not change our results. We are unable to confirm whether there are further changes in antibiotic clearance rates between 7 and 14 days of treatment because levels at the end of therapy have no clinical utility. In addition, we cannot ascertain whether the change in antibiotic clearance is an inducible process that occurs with each antibiotic exposure. Our analysis looked at the most recent admission during the given study period and included number of admissions during the study period in the regression analysis; the analysis revealed no statistical significance, suggesting no cumulative effects of repeated antibiotic treatments. However, this adjustment does not account for possible effects from admissions prior to the study period.
Conclusions
Increasing BL clearance rates during APE treatment in patients with CF frequently necessitates important dose increases to maximize efficacy. On the contrary, AMG clearance rates decreased, leading to a mean dose reduction to minimize antibiotic toxicity. Changes in BL and AMG clearance rates occur independent of renal function. Obtaining serum drug levels is essential to determining optimal dosing for individual patients because there is no correlation between antibiotic clearance rates and measures of renal function.
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